Strength Seen in BridgeBio Pharma (BBIO): Can Its 16.0% Jump Turn into More Strength?

Stock Performance - BridgeBio Pharma (BBIO) shares rallied 16% in the last trading session to close at $33 73, driven by notable trading volume [1] - The stock has gained 5 8% over the past four weeks [1] Financial Expectations - The company is expected to post a quarterly loss of$ 1 09 per share, representing a year-over-year change of -13 5% [2] - Revenues are expected to be $5 3 million, up 202 9% from the year-ago quarter [2] - The consensus EPS estimate for the quarter has been revised 4 1% lower over the last 30 days [3] Industry Comparison - BridgeBio Pharma is part of the Zacks Medical - Generic Drugs industry [3] - Bausch Health (BHC), another stock in the same industry, closed the last trading session 6 1% lower at$ 7 40 and has returned 0 9% in the past month [3] - For Bausch, the consensus EPS estimate for the upcoming report has changed +0 4% over the past month to $1 12, representing a change of -2 6% from the year-ago quarter [4] Drug Development and Commercial Progress - The stock price rise was attributed to encouraging commercial progress for its recently approved drug, Attruby (acoramidis), pipeline progress, and expected 2025 milestones [5] - Attruby received FDA approval in November 2024 as a near-complete TTR stabilizer to reduce cardiovascular death and cardiovascular-related hospitalization in adult patients with transthyretin amyloid cardiomyopathy [5] - The company has witnessed remarkable momentum for the drug with 430 patient prescriptions written by 248 physicians [5] - Approvals in other geographies for the same indication are anticipated in 2025 [5]